H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $21.00. The company’s shares opened today at $5.38.
Pantginis covers the Healthcare sector, focusing on stocks such as BioCardia, Krystal Biotech, and Panbela Therapeutics. According to TipRanks, Pantginis has an average return of -10.9% and a 29.40% success rate on recommended stocks.
PDS Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $20.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on PDS Biotechnology’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.53 million. In comparison, last year the company had a GAAP net loss of $5.82 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology (PDSB) Company Description:
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
- Cantor expects PDS ASTRO oral presentation to support PDS0101’s opportunity
- PDS Biotechnology announces data from IMMUNOCERV Phase 2 trial
- PDS data in Q3 could bring positive momentum, says B. Riley
- PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
